These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 29661415)

  • 41. Evidence Supporting Idarucizumab for the Reversal of Dabigatran.
    Pollack CV
    Am J Med; 2016 Nov; 129(11S):S73-S79. PubMed ID: 27568285
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
    Pollack CV; Reilly PA; Bernstein R; Dubiel R; Eikelboom J; Glund S; Huisman MV; Hylek E; Kam CW; Kamphuisen PW; Kreuzer J; Levy JH; Sellke F; Stangier J; Steiner T; Wang B; Weitz JI
    Thromb Haemost; 2015 Jul; 114(1):198-205. PubMed ID: 26020620
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.
    Marino KK; Santiago RA; Dew RB; Berliner N; Connors JM; Connell NT; Tucker JK
    Pharmacotherapy; 2016 Oct; 36(10):e160-e165. PubMed ID: 27581709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm.
    Tomaszuk-Kazberuk A; Łopatowska P; Młodawska E; van Ryn J; Reilly PA; Pollack CV
    Pol Arch Intern Med; 2017 Jan; 127(1):68-70. PubMed ID: 28146465
    [No Abstract]   [Full Text] [Related]  

  • 45. Successful intravenous thrombolysis for ischemic stroke after reversal of dabigatran anticoagulation with idarucizumab: a case report.
    Agosti S; Casalino L; Rocci E; Zaccone G; Rota E
    J Med Case Rep; 2017 Aug; 11(1):224. PubMed ID: 28806993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
    Jacquemin M; Toelen J; Schoeters J; van Horenbeeck I; Vanlinthout I; Debasse M; Peetermans M; Vanassche T; Peerlinck K; van Ryn J; Verhamme P
    J Thromb Haemost; 2015 Nov; 13(11):2087-92. PubMed ID: 26347330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant.
    Finks SW; Rogers KC
    Am J Med; 2017 May; 130(5):e195-e197. PubMed ID: 28011314
    [No Abstract]   [Full Text] [Related]  

  • 48. Cholestatic liver injury as a side-effect of dabigatran and the use of coagulation tests in dabigatran intoxication and after reversal by idarucizumab in bleeding and sepsis.
    Comuth WJ; Haase AM; Henriksen LØ; Malczynski J; van de Kerkhof D; Münster AB
    Scand J Clin Lab Invest; 2018; 78(1-2):1-5. PubMed ID: 29148292
    [TBL] [Abstract][Full Text] [Related]  

  • 49. No intravenous access, no problem: Intraosseous administration of tranexamic acid is as effective as intravenous in a porcine hemorrhage model.
    Lallemand MS; Moe DM; McClellan JM; Loughren M; Marko S; Eckert MJ; Martin MJ
    J Trauma Acute Care Surg; 2018 Feb; 84(2):379-385. PubMed ID: 29194320
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idarucizumab for the Reversal of Dabigatran.
    Gottlieb M; Khishfe B
    Ann Emerg Med; 2017 May; 69(5):554-558. PubMed ID: 28110992
    [No Abstract]   [Full Text] [Related]  

  • 52. Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".
    Kamel KS; Chin PK; Doogue MP; Barclay ML
    Clin Pharmacokinet; 2017 Feb; 56(2):207-208. PubMed ID: 28035591
    [No Abstract]   [Full Text] [Related]  

  • 53. Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran.
    Teleb M; Salire K; Wardi M; Alkhateeb H; Said S; Mukherjee D
    Cardiovasc Hematol Disord Drug Targets; 2016; 16(1):25-29. PubMed ID: 27477871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [The first use of iv. idarucizumab for dabigatran reversal in Hungary].
    Driesz L; Barabás É; Bodócs I; Szántó Z; Herr G; Bencsik G; Pál L; Borbola J
    Orv Hetil; 2017 Mar; 158(10):387-392. PubMed ID: 28270004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Idarucizumab: What Should We Know?
    Cortese F; Calculli G; Gesualdo M; Cecere A; Zito A; De Vito F; Carbonara R; Carbonara S; Cortese AM; Ciccone MM
    Curr Drug Targets; 2018; 19(1):81-88. PubMed ID: 28950812
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Structure-guided residence time optimization of a dabigatran reversal agent.
    Schiele F; van Ryn J; Litzenburger T; Ritter M; Seeliger D; Nar H
    MAbs; 2015; 7(5):871-80. PubMed ID: 26047352
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Idarucizumab (Praxbind) for Dabigatran (Pradaxa) Anticoagulant Reversal.
    Jarrett JB; Gimbar RP
    Am Fam Physician; 2017 Jun; 95(12):798-800. PubMed ID: 28671421
    [No Abstract]   [Full Text] [Related]  

  • 58. Anticoagulants: Updates on idarucizumab.
    Chandan JS; Thomas T; Baryah HS
    Br Dent J; 2017 Feb; 222(3):140-141. PubMed ID: 28184089
    [No Abstract]   [Full Text] [Related]  

  • 59. A Comparison of the Effects of Intraosseous and Intravenous 5% Albumin on Infusion Time and Hemodynamic Measures in a Swine Model of Hemorrhagic Shock.
    Muir SL; Sheppard LB; Maika-Wilson A; Burgert JM; Garcia-Blanco J; Johnson AD; Coyner JL
    Prehosp Disaster Med; 2016 Aug; 31(4):436-42. PubMed ID: 27210025
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Idarucizumab elimination of dabigatran minutes before systemic thrombolysis in acute ischemic stroke.
    Schulz JG; Kreps B
    J Neurol Sci; 2016 Nov; 370():44. PubMed ID: 27772783
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.